Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Ureteral involvement by metastatic malignant disease

Ureteral involvement by metastatic malignant disease Ureteral metastases from other primary cancers are very rare. Treatment of these metastases is difficult and outcomes are poor. A thorough literature review was done with the aim of finding characteristics that may influence survival rates of patients with ureteral metastases. Systematic literature searches of PubMed and Web of Science were performed in Jan 2019. A total of 79 papers that included 265 patients with cancer metastases to their ureters were finally considered for evidence synthesis. Prostate, bladder, breast, gut cancer and lymphoma were the predominant primary tumors. The median interval time from primary tumor diagnosis to ureter metastasis was 28.5 months. The median survival time after diagnosis of ureter metastasis was 18 months. Risk factors of survival were analyzed. Age, sex, hydronephrosis, ureter side, and segment were not associated with survival. Interval time and treatment were associated with overall survival. Further analysis indicated that patients who underwent surgery had better outcomes. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical & Experimental Metastasis Springer Journals

Ureteral involvement by metastatic malignant disease

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/ureteral-involvement-by-metastatic-malignant-disease-8rTCw2EsVr

References (88)

Publisher
Springer Journals
Copyright
Copyright © 2019 by Springer Nature B.V.
Subject
Biomedicine; Cancer Research; Biomedicine, general; Oncology; Hematology; Surgical Oncology
ISSN
0262-0898
eISSN
1573-7276
DOI
10.1007/s10585-019-09989-8
Publisher site
See Article on Publisher Site

Abstract

Ureteral metastases from other primary cancers are very rare. Treatment of these metastases is difficult and outcomes are poor. A thorough literature review was done with the aim of finding characteristics that may influence survival rates of patients with ureteral metastases. Systematic literature searches of PubMed and Web of Science were performed in Jan 2019. A total of 79 papers that included 265 patients with cancer metastases to their ureters were finally considered for evidence synthesis. Prostate, bladder, breast, gut cancer and lymphoma were the predominant primary tumors. The median interval time from primary tumor diagnosis to ureter metastasis was 28.5 months. The median survival time after diagnosis of ureter metastasis was 18 months. Risk factors of survival were analyzed. Age, sex, hydronephrosis, ureter side, and segment were not associated with survival. Interval time and treatment were associated with overall survival. Further analysis indicated that patients who underwent surgery had better outcomes.

Journal

Clinical & Experimental Metastasis – Springer Journals

Published: Aug 24, 2019

There are no references for this article.